Exploring the regulatory impact of insulin on type I collagen synthesis in hepatic stellate cells through α5β1 integrin

Abstract

In the present study by Dodig and colleagues, published in Metabolism and Target Organ Damage, the authors investigate the role of insulin in promoting type I collagen synthesis in hepatic stellate cells (HSCs) through α5β1 integrin signaling. Using L-SACC1 transgenic mice, which exhibit hyperinsulinemia and insulin resistance without fasting hyperglycemia, the researchers demonstrate that elevated insulin levels significantly increase type I collagen production in HSCs. This effect is mediated by α5β1 integrin signaling rather than the PI3 kinase pathway. These findings suggest that chronic hyperinsulinemia may preprogram HSCs for enhanced fibrogenesis following liver injury, contributing to advanced fibrosis associated with metabolic disorders such as metabolic dysfunction-associated steatosis liver disease (MASLD) and type 2 diabetes. It further suggests that chronic hyperinsulinemia increases the risk of significant fibrosis burden in chronic liver disease. In this commentary, the strengths and limitations of this study are discussed, along with the potential impact of these findings on current treatment strategies for insulin resistance, endogenous hyperinsulinemia, and exogenous hyperinsulinemia in the development of MASLD and disease progression to fibrosis, cirrhosis, and hepatocellular carcinoma.

Keywords

Insulin resistance / integrins / collagen / fibrosis / cirrhosis / MASLD

References

[1] Aldroubi BG,Youssef TS.Cell-specific regulation of insulin action and hepatic fibrosis by CEACAM1.Metab Target Organ Damage2024;4:34 PMCID:PMC11619085

[2] Chandrasekaran P.Diabetes mellitus and heart disease.Metab Target Organ Damage2024;4:18

[3] Lonardo A,Baffy G.Liver fibrosis as a barometer of systemic health by gauging the risk of extrahepatic disease.Metab Target Organ Damage2024;4:41

[4] Bourebaba N.Hepatic stellate cells role in the course of metabolic disorders development - a molecular overview.Pharmacol Res2021;170:105739

[5] Cai CX,Castelino-Prabhu S.Activation of insulin-PI3K/Akt-p70S6K pathway in hepatic stellate cells contributes to fibrosis in nonalcoholic steatohepatitis.Dig Dis Sci2017;62:968-78

[6] Kaji K,Ikenaka Y.Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats.J Gastroenterol2014;49:481-91

[7] Kaya D,Tsuji Y.TGR5 activation modulates an inhibitory effect on liver fibrosis development mediated by anagliptin in diabetic rats.Cells2019;8:1153.

[8] Zhang F,Kong D.Tetramethylpyrazine reduces glucose and insulin-induced activation of hepatic stellate cells by inhibiting insulin receptor-mediated PI3K/AKT and ERK pathways.Mol Cell Endocrinol2014;382:197-204

[9] Creeden JF,Xu M.Hepatic kinome atlas: an in-depth identification of kinase pathways in liver fibrosis of humans and rodents.Hepatology2022;76:1376-88 PMCID:PMC9489820

[10] Kitsios K,Antza C,Sarigianni M.Treatment of metabolic (dysfunction)-associated fatty liver disease: evidence from randomized controlled trials-a short review.Metab Syndr Relat Disord2024;22:703-8

[11] Jiang Y,Zhu X,Gao X.Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics.Lipids Health Dis2024;23:95

[12] Dodig M,Dasarathy S.Insulin increases type I collagen synthesis in hepatic stellate cells via α5β1 integrin.Metab Target Organ Damage2024;4:49

[13] Poy MN,Rezaei K.CEACAM1 regulates insulin clearance in liver.Nat Genet2002;30:270-6

[14] Park SY,Kim HJ.Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1.Am J Physiol Endocrinol Metab2006;291:E517-24

[15] Walsh A,Breslow JL.High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human HDL3.J Biol Chem1989;264:6488-94

[16] Nishimichi N,Kanno K.Induced hepatic stellate cell integrin, α8β1, enhances cellular contractility and TGFβ activity in liver fibrosis.J Pathol2021;253:366-3 PMCID:PMC7986747

[17] Kohli R.NASH animal models: are we there yet?.J Hepatol2011;55:941-3

[18] Weiskirchen R.Liver fibrosis: from pathogenesis to novel therapies.Dig Dis2016;34:410-22

[19] Jamalinia M,Weiskirchen R.Sex and gender differences in liver fibrosis: pathomechanisms and clinical outcomes.Fibrosis2024;2:10006

[20] Turaga RC,Sharma M.Targeting integrin αvβ3 by a rationally designed protein for chronic liver disease treatment.Commun Biol2021;4:1087 PMCID:PMC8445973

[21] Yokosaki Y.New therapeutic targets for hepatic fibrosis in the integrin family, α8β1 and α11β1, induced specifically on activated stellate cells.Int J Mol Sci2021;22:12794 PMCID:PMC8657911

[22] Ulmasov B,Carmichael P,Griggs DW.An inhibitor of arginine-glycine-aspartate-binding integrins reverses fibrosis in a mouse model of nonalcoholic steatohepatitis.Hepatol Commun2018;3:246-61 PMCID:PMC6357833

[23] Slack RJ,Roper JA,Hatley RJD.Emerging therapeutic opportunities for integrin inhibitors.Nat Rev Drug Discov2022;21:60-78 PMCID:PMC8446727